Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1086/599042 http://scihub22266oqcxt.onion/10.1086/599042 19441978!ä!19441978 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Infect+Dis 2009 ; 48 (12): 1713-23 Nephropedia Template TP {{tp|p=19441978|t=2009. Neurologic manifestations associated with parvovirus B19 infection |pdf=|usr=}}{{19441978}} gab.com Text Neurologic manifestations associated with parvovirus B19 infection JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=19441978 #FOAvip Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P= .002), rash (OR, 11.5; P< .001), and peripheral nervous system involvement (OR, 12.1; P= .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P= .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81% of samples) and serum (85%), whereas specific antibodies were found in 33% of cerebrospinal fluid samples. Neurologic sequelae occurred in 22% of 77 patients with a known outcome, and some improvement occurred in 16%. No differences in the prevalence of sequealae were noted between immunocompetent patients (21% of whom experienced sequealae) and patients with altered immunity (25%) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died. Twit Text FOAVip Neurologic manifestations associated with parvovirus B19 infection ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=19441978 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=19441978 #FOAvip English Wikipedia <ref>{{Cite pmid|19441978}}</ref> Neurologic manifestations associated with parvovirus B19 infection #MMPMID19441978 Douvoyiannis M; Litman N; Goldman DL Clin Infect Dis 2009[Jun]; 48 (12): 1713-23 PMID19441978show ga Eighty-one cases of neurologic disease, including encephalitis, meningitis, stroke, and peripheral neuropathy, that were associated with parvovirus B19 infection were reviewed. Most patients were children, and two-thirds had central nervous system manifestations. One-third had altered immunity. Viral symptoms (odds ratio [OR], 5.7; P= .002), rash (OR, 11.5; P< .001), and peripheral nervous system involvement (OR, 12.1; P= .004) were more frequent in immunocompetent patients. Brain magnetic resonance imaging abnormalities were more frequent in patients with altered immunity (OR, 10; P= .04). In central nervous system disease, parvovirus B19 DNA was commonly detected in cerebrospinal fluid (81% of samples) and serum (85%), whereas specific antibodies were found in 33% of cerebrospinal fluid samples. Neurologic sequelae occurred in 22% of 77 patients with a known outcome, and some improvement occurred in 16%. No differences in the prevalence of sequealae were noted between immunocompetent patients (21% of whom experienced sequealae) and patients with altered immunity (25%) or between patients with central nervous system manifestations who received intravenous immunoglobulin with or without steroids and those patients with central nervous system manifestations who did not. Five patients died. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Central Nervous System Diseases/diagnosis/*epidemiology/mortality/virology[MESH] |Child[MESH] |Child, Preschool[MESH] |Female[MESH] |Humans[MESH] |Infant[MESH] |Infant, Newborn[MESH] |Male[MESH] |Middle Aged[MESH] |Parvoviridae Infections/*complications/*virology[MESH] |Parvovirus B19, Human/*isolation & purification[MESH] |Peripheral Nervous System Diseases/diagnosis/*epidemiology/virology[MESH] |Prevalence[MESH] |Treatment Outcome[MESH]Neurologic manifestations associated with parvovirus B19 infection (epmc).pdf DeepDyve Pubget Overpricing